ArticleRadiologie (Heidelberg, Germany)2025
[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].
Article in Radiologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite chemoimmunotherapy and autologous stem cell transplants, 30-40% of all patients with aggressive B‑cell non-Hodgkin lymphoma relapse.
objectiveThe use of targeted therapies is necessary to optimize the survival of these patients.
resultsChimeric antigen receptor (CAR) T‑cell therapies directed against CD19 are increasingly changing the therapeutic landscape for patients with diffuse large B‑cell lymphoma (DLBCL) and other B‑cell non-Hodgkin lymphomas. Follow-up data show that 30-40% of patients with relapsed or refractory aggressive lymphomas remain disease-free and can be cured in the long term after CAR-T cell therapy. Increasingly improved management of side effects, e.g., cytokine release syndrome (CRS) and neurotoxicity (immune effector cell-associated neurotoxicity syndrome, ICANS), by trained teams improves treatment safety. Bispecific antibodies are also targeted therapies that bind and activate CD3 effector T‑cells and assemble them into B‑cell antigens in the sense of an immunological synapse, resulting in cell-dependent cytotoxicity. Some of these drugs are also approved for aggressive and some for indolent B‑cell non-Hodgkin lymphoma; they are available off the shelf and can also be used in particular for older and less fit patients.
conclusionBoth treatment options have significantly improved the prognosis of patients with lymphoma and generally have lower toxicities.
Indexed as
Identifiers
40514410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.